Although synergy between chemical drugs and TRAIL in killing cancer cells has been extensively reported in vitro (Stolfi et al., 2012; Wong et al., 2019), combined with chemical drugs did not improve the antitumor effect of TRAIL in CRC patients, which was predominantly attributed to the limitation of chemical drugs in sensitizing cancer cells to TRAIL (Wainberg et al., 2013). The gene discussed is TNFSF10; the disease is cancer.